Company News

In this article uMed’s CEO Matt Wilson discusses the untapped potential of harnessing data-led insights to drive personalized, meaningful consumer experiences within the healthcare sector. He examines how tailored communication and bespoke engagement throughout a patient’s healthcare journey has the potential to enhance health outcomes and reduce provider costs. And how it’s the key to…

A great article from our CEO Matt Wilson featured in The Journal of mHealth on the use of technology to address the challenges of access to clinical trial participation in underserved communities. The article emphasizes the need to support smaller, local healthcare providers that serve as a gateway to underrepresented, less wealthy communities, to build…

uMed Partners with The Michael J. Fox Foundation to Support Wide-scale Study Exploring Link Between Smell Loss and Parkinson’s uMed partners with The Michael J. Fox Foundation to run its smell test study in the UK as part of a global programme to explore the link between smell loss and Parkinson’s disease uMed will enroll…

Our Future Health partners with uMed to facilitate recruitment of volunteers across the South of the UK uMed is delighted to announce it is now engaging volunteers for Our Future Health, the UK’s largest health research programme, designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of…

Late-stage industry clinical research in the UK fell by 41% between 2017 and 2021, which is putting future patient care at risk The healthtech’s latest round of funding will directly combat this problem by accelerating research and care support for targeted patient groups through its landmark cohort programmes The successful raise will also be used…

Partnership introduces unique patient recruitment and engagement platform to Canada TORONTO, March 09, 2023 (GLOBE NEWSWIRE) — MCI Onehealth Technologies Inc. (“MCI”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and uMed, the UK-based provider of a leading automated patient-recruitment platform, are pleased to announce a partnership…

NEW YORK, August 29, 2022 — A first-of-its-kind patient cohort platform will soon be available to UK and US researchers struggling to recruit patients with interstitial lung disease (ILD), such as pulmonary fibrosis and progressing fibrosis resulting from COVID-19. UK-based company uMed announced the launch of the Access-ILD/PF Cohort at the sixth annual Idiopathic Pulmonary…

An article published in the Journal of Clinical Studies describing the benefits of uMed in clinical trial recruitment

An automated patient recruitment platform (ARP) could help researchers recruit patients significantly faster into clinical studies across diverse disease areas, helping researchers identify new treatments for diseases more quickly, tech platform creator uMed says.

Pharma Business International features uMed CEO Matt Wilson. He discusses uMed’s growth as a health technology company and the importance of building trust with all stakeholders.